Bruesewitz v. Wyeth, 562 U.S. 223 (2011), is a United States Supreme Court case that decided whether a section of the National Childhood Vaccine Injury Act of 1986 preempts all vaccine design defect claims against vaccine manufacturers .


Feb 22, 2011 ... BRUESEWITZ et al. v. WYETH LLC, fka WYETH, INC., et al. certiorari to ... Held: The NCVIA preempts all design-defect claims against vaccine ...


Holding: The National Childhood Vaccine Injury Act, which created a no-fault program to provide compensation for vaccine-related injuries, preempts all ...


Apr 21, 2009 ... 15 See James M. Wood et al., Product Liability Protection for Stem Cell Research and ...... FDA preemption and common law tort claims is Wyeth v. ...... 389 See DEBBIE BOoKCHiN & JIM SCHUMACHER, THE VIRUS AND ...


William F. Bothwell et al., Plaintiffs and Appellants, v. ... J. Thomasch, Richard W. Mark, and Lauren J. Elliot for Defendant and Respondent Wyeth. ... Matthew A. Schumacher and John W. Shaw, Los Angeles, for Defendant and Respondent ...


Feb 15, 2008 ... Rapamycin (Wyeth Pharmaceuticals) was diluted in a ... After 2 months of treatment, all mice were ..... Schumacher V,Vogel T, Leube B, et al.


Sirolimus and tacrolimus were generously provided by Wyeth-Pharma GmbH ..... Guido Schumacher, Marijke Oidtmann, Dietmar Jacob, Sven Jonas, Jan M. ... Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, et al.


Perez · insert_drive_fileCom. v. Daniels · insert_drive_fileREINHART v. SAPP · insert_drive_fileKennedy v. Butler Memorial Hosp · insert_drive_fileIn re E.T ...


Apr 6, 2010 ... Endpoints included the proportion of all subjects with sUA <6.0 mg/dL and the proportion of ... Becker et al.; licensee BioMed Central Ltd. 2010.